Nexstone Immunology is a clinical-stage biopharmaceutical company focused on the development and commercialization of anti-inflammatory/immunology programs in areas of significant unmet medical need. Our lead asset is a monoclonal antibody targeting critical inflammatory pathways. We are currently planning our development program which will evaluate the compound in a broad array of immune-mediated diseases.